Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2011.41.0332 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Activation of HSPA5 contributes to pazopanib-induced hepatotoxicity through l-ornithine metabolism pathway and endoplasmic reticulum stress.
J Pharm Pharmacol
November 2024
Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Objectives: The clinical application of Pazopanib (Paz) is often accompanied by hepatotoxicity. However, the mechanisms of hepatic toxicity induced by pazopanib are not entirely clarified.
Methods: Male C57BL/6J mice were treated with pazopanib every day for 2, 4, or 8 weeks.
Pazopanib-induced trismus in a young male with metastatic renal cell carcinoma: a case report and literature review.
Oxf Med Case Reports
January 2024
Medical Oncology Department, Mohammed VI University Hospital, Marrakech, Morocco.
The treatment landscape of advanced kidney cancer has radically changed over the years. Targeting tumor angiogenesis from historical cytokines to multi-tyrosine kinase inhibitors and recently the advent of immunotherapy resulted in a radical improvement in survival but presented substantial challenges in terms of toxicity management. In countries where the access to immune checkpoints inhibitors is still very limited, tyrosine-kinase inhibitors remain the optimal choice.
View Article and Find Full Text PDFRadiation recall myositis with pazopanib in a patient with soft tissue sarcoma.
J Oncol Pharm Pract
June 2023
Department of Radiation Oncology, Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, İstanbul, Turkey.
Introduction: Radiation recall reaction is an acute inflammatory reaction confined to previously irradiated areas that are most commonly triggered by the administration of anti-cancer agents after radiotherapy. Radiation recall myositis is a relatively rare form of radiation recall reaction.
Case Report: Here we report a 29-year-old female patient who suffered from metastatic monophasic synovial sarcoma.
Pazopanib-Induced Liver Injury in Patients With Metastatic Renal Cell Carcinoma: A Report of Two Cases.
Cureus
December 2022
Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, JPN.
We report two cases of pazopanib (PAZ)-induced liver injury in patients with metastatic renal cell carcinoma. The first patient was a 70-year-old female who was diagnosed with right renal cell carcinoma and showed tumor embolism in the inferior vena cava. PAZ was started but discontinued after about one month due to a grade four liver injury.
View Article and Find Full Text PDFPazopanib-induced severe acute liver injury: A case report.
Medicine (Baltimore)
November 2021
Department of Pathology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University School of Medicine, Bucheon, Republic of Korea.
Rationale: Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the United States. Painkillers and fever antipyretics are the most common cause of DILI. Hepatic injury can be provoked by DILI as hepatocellular or cholestatic type.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!